Hengrui Pharmaceuticals
-
How effective is Hengrui’s vunakizumab, the first NMPA-approved anti-IL-17A monoclonal antibody developed in China?
Vunakizumab is a self-developed product of Hengrui Pharmaceuticals, being the first domestically developed recombinant anti-IL-17A humanized monoclonal antibody approved in China, and also the first innovative drug launched by Hengrui in the field of autoimmune diseases
-
What is the Current Landscape of Obesity Drug Development in China?
These presentations indicate that the era of domestically developed GLP-1 drugs for weight loss in China is on the horizon, with significant implications for the future of obesity treatment
